Erectile dysfunction therapy is undergoing a cost transformation in the United States as rising insurance premiums shift affordability for patients. Fildena, a popular sildenafil-based treatment, is now caught in the broader economic changes affecting prescription drug coverage, out-of-pocket payments, and policy reforms. This article examines how insurance cost dynamics are reshaping Fildena...